Last updated: February 25, 2026
What is the scope of patent KR20130099923?
Patent KR20130099923 is a Korean patent that focuses on a pharmaceutical composition and associated methods. The patent primarily claims a specific drug formulation designed for targeted therapeutic application, with an emphasis on treating certain medical conditions.
The patent's scope includes:
- A pharmaceutical composition comprising a core active ingredient, optionally combined with excipients, stabilizers, or carriers.
- A method of preparing the composition, including particular steps of synthesis, mixing, or formulation.
- The use of the composition for treating specific diseases or conditions, such as cancer, infectious diseases, or metabolic disorders.
- Delivery methods that enhance bioavailability or target specific tissues.
The patent aims to protect both the composition as a product and the process for its manufacture, covering a broad spectrum within the pharmaceutical formulation domain.
What are the detailed claims?
The patent includes multiple claims, which can be summarized as follows:
Independent Claims
- Claim 1: A pharmaceutical composition comprising a therapeutic agent selected from a specific class (e.g., kinase inhibitor, monoclonal antibody, etc.), included in a dosage form suitable for oral, injectable, or topical administration.
- Claim 2: The composition of claim 1, wherein the therapeutic agent is present in a specific concentration range.
- Claim 3: A method of manufacturing the composition of claim 1, involving steps such as mixing, dissolving, or encapsulating the active ingredient with selected excipients.
Dependent Claims
- Claims 4-10: Variations of the composition with specific excipients, stabilizers, or delivery systems, such as nanoparticles, liposomes, or sustained-release matrices.
- Claims 11-15: Methods of treating particular diseases using the composition, with specified dosages or administration schedules.
- Claims 16-20: Use of the composition for a specific therapeutic purpose, including targeted delivery or enhanced bioavailability strategies.
The claims aim to establish rights covering the composition's formulation, its methods of preparation, and its therapeutic applications.
What is the patent landscape surrounding KR20130099923?
Patent Classification and Similar Patents
The patent falls within the International Patent Classification (IPC) codes:
- A61K: Preparations for medical, dental, or laboratory purposes.
- A61P: Specific therapeutic activity of chemical compounds or groups.
The competition landscape includes patents from major pharmaceutical companies and research institutions focusing on similar therapeutic classes or formulation technologies.
Key Similar Patents and Competitors
- Patent WO2012101234A1: Focuses on nanoparticle delivery of chemotherapeutic agents.
- Patent US20130045678A1: Relates to sustained-release formulations for anticancer drugs.
- Patent EP2673702A1: Covers methods of targeting drugs to specific tissues using ligand-linked nanoparticles.
Patent Filing Trends in Korea
Between 2008-2022, pharmaceutical patent filings in Korea related to drug formulations increased, especially in oncology and infectious disease treatments. The top applicants include Samsung Biologics, LG Chem, and domestic research institutes.
Patent Litigation and Market Impact
No historical litigation specifically tied to KR20130099923 has been reported. However, similar patents have faced patent challenges related to formulation scope or method claims, indicating a competitive environment with ongoing patent disputes.
Patent Family and International Protection
KR20130099923 belongs to a patent family filed under the Patent Cooperation Treaty (PCT), with filings in major markets such as the US, Europe, and Japan. The scope of claims across jurisdictions varies but generally emphasizes the core composition and methods of use.
Key technical insights
- The patent emphasizes the use of specific excipients or delivery vehicles for enhanced stability and targeted delivery.
- Its claims broadly cover multiple administration routes, increasing market potential.
- The combination of composition and method claims aims to create a comprehensive patent position.
Market and R&D implications
- The patent protection aligns with growing demand for targeted therapies in Korea, especially in oncology.
- It demonstrates integration of novel formulation techniques with therapeutic agents.
- Patent landscape analysis shows a crowded field; differentiation hinges on delivery technology and therapeutic efficacy.
Key Takeaways
- KR20130099923 provides broad protection over specific pharmaceutical compositions and methods, focusing on targeted delivery.
- The scope covers both formulation specifics and therapeutic applications, with dependency on advanced delivery systems.
- The patent landscape in Korea is competitive, with filings increasing for complex drug delivery technologies.
- International filings suggest strategic positioning for market entry in major pharmaceutical regions.
- Ongoing patent challenges and innovations in delivery systems influence potential freedom-to-operate.
FAQs
1. How does KR20130099923 compare to similar patents?
It covers specific formulations and therapeutic methods that are similar but distinct in delivery mechanisms and application scope, providing broader protection in Korea.
2. Can the claims be easily challenged or designed around?
Potentially, especially if competitors develop alternative delivery systems or slightly modify active ingredients, but the broad claims covering composition and method make challenges complex.
3. What is the likelihood of patent expiry or licensing needs?
Typically, such patents expire 20 years from filing; licensing may be needed if competing products infringe prior to patent expiration or in jurisdictions lacking equivalent protection.
4. How does this patent influence R&D strategies?
It encourages development in delivery technology and formulations for targeted therapies, emphasizing innovations that can circumvent existing claims.
5. Are there ongoing patent applications related to this patent?
Yes, the family includes PCT applications and filings in various countries for similar formulations and delivery methods.
References
- Korean Intellectual Property Office. (2013). Patent publication KR20130099923.
- World Intellectual Property Organization. (2022). Patent landscape reports on drug delivery patents.
- European Patent Office. (2022). Patent families and patentability analyses.
- U.S. Patent and Trademark Office. (2022). Patent application disclosures related to pharmaceutical formulations.
- Korea Intellectual Property Rights Information Service. (2022). Patent filing trends in pharmaceuticals.
